• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

enGene Therapeutics Inc. - Common Stock (NQ:ENGN)

1.710 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,300
Open 1.710
Bid (Size) 1.700 (400)
Ask (Size) 1.760 (1,000)
Prev. Close 1.710
Today's Range 1.710 - 1.710
52wk Range 1.400 - 12.25
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path ↗
Today 1:02 EDT
enGene (NASDAQ:ENGN) used a company webinar to outline preclinical findings for its investigational non-viral gene therapy, detalimogene voraplasmid, used with a polidocanol surfactant bladder rinse,... 
Via MarketBeat
News headline image
enGene to Host KOL Webinar on October 15, 2026
October 13, 2026
From enGene Therapeutics Inc.
Via Business Wire

Performance

52-Week Range 86.0% below 52-week high
1.710
1.4052W Low 12.2552W High
1 Week 5.5% below 1-week high
1.561W Low 1.811W High

enGene Therapeutics Inc. - Common Stock (ENGN) traded between $1.40 and $12.25 over the past 52 weeks and last traded at $1.71, 86.0% below its 52-week high. Over the past week it ranged between $1.56 and $1.81.

Past 12 Months
-1.2%
-9.5%
-10.9%
-78.8%
-80.7%
-80.6%
1W -$0.02
1M -$0.18
3M -$0.21
6M -$6.37
YTD -$7.14
1Y -$7.09

ENGN was -80.6% over the past year, -78.8% over six months, -80.7% year to date, -1.2% in the last week.

12 Months vs Market
ENGN
-80.6%
DIA
+12.6%
SPY
+16.0%
QQQ
+20.9%
IWM
+9.9%

Over the past 12 months ENGN returned -80.6% versus DIA (Dow) +12.6%, SPY (S&P 500) +16.0%, QQQ (Nasdaq 100) +20.9% and IWM (Russell 2000) +9.9%.

Volume & Liquidity 0.01× 3-mo avg
Today 9,300 3-mo avg 729.8K
1W
771.3K
1M
787.5K
3M
729.8K
6M
1.3M
YTD
975.1K
1Y
1.1M

ENGN most recently traded 9,300 shares against a 3-month average daily volume of 729.8K.

More News

Read More
News headline image
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
September 08, 2026
From enGene Therapeutics Inc.
Via Business Wire
News headline image
enGene to Participate in Upcoming Investor Conferences
September 01, 2026
From enGene Therapeutics Inc.
Via Business Wire
News headline image
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market ↗
August 13, 2026
Via MarketBeat
News headline image
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
August 04, 2026
From enGene Therapeutics Inc.
Via Business Wire
News headline image
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
July 16, 2026
From enGene Therapeutics Inc.
Via Business Wire
News headline image
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
June 15, 2026
From enGene Therapeutics Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
June 02, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
May 30, 2026
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
May 30, 2026
Via The Motley Fool
News headline image
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
May 29, 2026
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
May 26, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
May 19, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares ↗
May 15, 2026
Via The Motley Fool
Topics Regulatory Compliance
Unusual volume stocks are being observed in Monday's session. ↗
May 11, 2026
Via Chartmill
News headline image
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain ↗
May 08, 2026
Via MarketBeat
Which stocks are experiencing notable movement on Thursday? ↗
May 07, 2026
Via Chartmill
Top stock movements in today's session. ↗
May 07, 2026
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
May 07, 2026
Via Chartmill
Which stocks are moving before the opening bell on Thursday? ↗
May 07, 2026
Via Chartmill
News headline image
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
May 07, 2026
From enGene Therapeutics Inc.
Via Business Wire
News headline image
enGene Announces Name Change to enGene Therapeutics Inc.
April 07, 2026
From enGene Therapeutics Inc.
Via Business Wire
News headline image
This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗
March 21, 2026
Via The Motley Fool
News headline image
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
March 09, 2026
From enGene Holdings Inc.
Via Business Wire

Frequently Asked Questions

Is enGene Therapeutics Inc. - Common Stock publicly traded?
Yes, enGene Therapeutics Inc. - Common Stock is publicly traded.
What exchange does enGene Therapeutics Inc. - Common Stock trade on?
enGene Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for enGene Therapeutics Inc. - Common Stock?
The ticker symbol for enGene Therapeutics Inc. - Common Stock is ENGN on the Nasdaq Stock Market
What is the current price of enGene Therapeutics Inc. - Common Stock?
The current price of enGene Therapeutics Inc. - Common Stock is 1.710
When was enGene Therapeutics Inc. - Common Stock last traded?
The last trade of enGene Therapeutics Inc. - Common Stock was at 10/15/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap